We describe the successful treatment of a 20-year-old patient with chronic granulomatous disease (CGD), by unrelated bone marrow transplantation (UBMT). The patient is relatively old compared to other CGD patients treated with BMT. He had had repeated serious infections from early childhood and was diagnosed as CGD, gp91-phox deficiency. Prolonged antibiotic-resistant pneumonitis worsened when the patient was 18 years old. In addition, he suffered Aspergillus osteomyelitis and acute renal failure due to amphotericin B. He received 94 granulocyte transfusions from 94 adult donors and the infections gradually improved. In September 1998, at 20 years of age, he underwent UBMT from an HLA 6 antigen-matched male donor, with CY and TBI conditioning. He received MTX and CsA as prophylaxis against GVHD. No serious complications occurred and rapid engraftment was achieved. Acute GVHD (grade 2, at day 19) and chronic GVHD (limited, at day 192) occurred. However, both were easily controlled. The patient is alive and well with no late rejection 26 months after UBMT. Bone Marrow Transplantation (2001) 28, 83-87. Keywords: chronic granulomatous disease; unrelated bone marrow transplantation; aspergillosis; granulocyte transfusions Chronic granulomatous disease (CGD) is a primary immunodeficiency disease characterized by recurrent severe bacterial and fungal infections during early childhood. CGD is caused by dysfunctional phagocytosis that is a result of defective NADPH oxidase. Deficiency of this oxidase causes a marked reduction in the phagocyte respiratory burst resulting in defective microbial killing. IFN-␥, supportive therapy and prophylactic administration of therapeutic agents such as sulfamethoxazole-trimethoprim have improved the prognosis.
Chronic granulomatous disease (CGD) is a primary immunodeficiency disease characterized by recurrent severe bacterial and fungal infections during early childhood. CGD is caused by dysfunctional phagocytosis that is a result of defective NADPH oxidase. Deficiency of this oxidase causes a marked reduction in the phagocyte respiratory burst resulting in defective microbial killing. IFN-␥, supportive therapy and prophylactic administration of therapeutic agents such as sulfamethoxazole-trimethoprim have improved the prognosis. [1] [2] [3] [4] However, control of therapy- There has been an increase in the number of reports of successful hematopoietic stem cell transplantation (HSCT) for patients with CGD. [5] [6] [7] [8] [9] [10] [11] [12] Most of these patients receive transplants from HLA-identical siblings during the first decade. There are few reports of unrelated bone marrow transplantation (UBMT). 7 We describe a successful UBMT to treat a 20-year-old patient with CGD. The UBMT was performed after granulocyte transfusions controlled therapy-resistant pneumonitis and Aspergillus osteomyelitis.
Case report

Clinical course before UBMT
An 18-year-old boy was hospitalized because of recurrent pneumonitis in December 1996. He had had repeated bacterial infections beginning at 2 months of age and was diagnosed with CGD (gp91-phox deficiency) at 1 year of age. Although he received prophylactic sulfamethoxazole-trimethoprim, he required about 20 hospital admissions and several granulocyte transfusions because of serious pneumonitis and other life-threatening infections (Figure 1 ). At 12 years of age he was treated unsuccessfully with IFN-␥. Since 16 years of age he had suffered from prolonged antibiotic-resistant pneumonitis. Upon admission in December 1996, his c-reactive protein (CRP) was 45 mg/l and erythrocyte sedimentation rate (ESR) 65 mm/h. Although he received antibiotic and ␥-globulin treatment for 1 month, his pneumonitis worsened in January 1997 (CRP 115 mg/l; ESR 109 mm/h, Figure 2a) . He then received 20 granulocyte transfusions from healthy volunteer donors between January and March. About 10 days after the 20th transfusion he suffered from headache and frontal swelling. Skull X-rays showed multiple osteolytic lesions of the frontal cranial region. CT and MRI revealed osteomyelitis and a subcutaneous abscess (Figure 2b ). Aspergillus fumigatus was cultured from the abscess. The fungal abscess was treated with intravenous amphotericin B at first, but this was discontinued due to acute renal failure (blood urea nitrogen (BUN), 13 .0 mmol/l; creatinine Bone Marrow Transplantation (Cre), 217 mol/l). The osteomyelitis gradually improved with oral administration of amphotericin B (2400 mg/day) and 74 granulocyte transfusions from 74 healthy volunteer between April and August 1997. The serum concentration of amphotericin B was 0.6 g/ml in June 1997. This value was in the same range as the cases who had received lowdose intravenous amphotericin B prophylactically. 13 Because of the lack of HLA-matched related donors, we discussed the possibility of UBMT with the patient and his parents. Although his age, the presence of infection and organic dysfunction were negative risk factors for UBMT, the patient chose UBMT after his condition had stabilized.
Clinical course of UBMT
In September 1998, at 20 years of age, he underwent UBMT from an HLA matched male (HLA-A, B, DR serologically identical, and HLA-DRB1 identical by the use of high resolution typing). Before UBMT laboratory studies showed mild inflammation: CRP was 4 mg/l, and ESR 19 mm/h. CT and MRI findings showed resolution of the osteomyelitis (Figure 2c ), but bilateral pulmonary consolidations still remained (Figure 2d ). Pulmonary function tests revealed mild restrictive ventilatory impairment (forced vital capacity was 77.0%). Renal dysfunction improved up to 0.74 mmol/l of BUN and 74.3 mol/l of Cre. Renogram findings showed delayed excretion from the left kidney and mild renal dysfunction. Figure 3 shows the clinical UBMT course. The conditioning regimen included CY 60 mg/kg/day ϫ 2 days and TBI 2 Gy ϫ 2/day ϫ 3 days (total 12 Gy). The marrow transplant contained 3.9 ϫ 10 8 nucleated cells/kg. Both patient and donor were blood group A positive. GVHD prophylaxis was short-term MTX (10 mg/m 2 /day i.v. on day 1, 7 mg/m 2 /day i.v. on days 3, 6 and 11), and CsA (3 mg/kg/day). For antifungal prophylaxis, the patient received oral amphotericin B 2400 mg/day and flucytosine 6000 mg/day, and inhaled amphotericin B. He was febrile (Ͼ38°C) for 3 days, with a maximum CRP of 52 mg/l. Despite daily platelet transfusions, his platelet count did not reach 10 ϫ 10 9 /l for 6 days. Because of frequent granulocyte transfusions the patient was at great risk of developing anti-HLA antibodies, but none were detected and there were no bleeding complications. Neutrophil counts reached 5 ϫ 10 9 /l on day 17, and platelet counts increased to 20 ϫ 10 9 /l on day 24. Acute GVHD (grade 2, skin and gut) occurred on day 19, but improved with methylprednisolone (20 mg/kg/day) and tacrolimus (0.075 mg/kg/day). His renal function worsened (Cre, 141 mol/l) due to tacrolimus, but improved gradually. On day 192 he developed a skin rash and was diagnosed with chronic GVHD (limited). It was rapidly controlled with an increase in the dose of tacrolimus. Twelve months after UBMT his renal function was almost normal, and mild asymptomatic restrictive ventilatory impairment continued.
Chimerism study of the BM by typing of variable number tandem repeat polymorphisms showed donor type on day 61 and day 370. Hydrogen peroxidase production per PMN following Staphylococcus aureus ingestion before UBMT, on day 44, and day 114 after UBMT was 0.0, 83.7 and 109.9, respectively (control, 92.5 Ϯ 11.7). Cytochrome b presence in PMN by monoclonal antibody (7D5) before UBMT, on day 44, and on day 114 after UBMT was 1.3%, 83.4% and 96.2%, respectively.
The patient is alive and well with a 100% Karnofsky score. There has been no late rejection, or any bacterial or fungal infections for 26 months after UBMT.
Discussion
The case concerns the first patient with CGD in Japan to be treated with UBMT, and the fourth worldwide. He is also the oldest patient with CGD to receive HSCT.
There are three other reports of UBMT treatment for CGD, 7, 14, 15 two of which rejected. The first is that of a 2-year-old boy treated in 1973.
14 He received CY (60 mg/kg ϫ 4 days) as conditioning. On day 90 after UBMT the NBT-positive cells were 12% and 3 years later he was alive, but in relapse. The second case is that of a boy with systemic aspergillosis, transplanted in 1975 with CY and selective pelvic irradiation as conditioning. 15 After UBMT the aspergillosis resolved, but he rejected the transplant 3 months later. The third case is that of an 8-month-old boy, who received CY (75 mg/kg ϫ 4 days) and busulfan (4 mg/kg ϫ 4 days) conditioning and donor buffy coat. 7 The patient achieved 100% engraftment and was alive with normal neutrophil function 36 months after UBMT.
HSCT of patients with CGD carries a high risk of graft failure. There are more than 10 cases of HSCT from HLAmatched siblings. 12 Many of them were conditioned with busulfan ϩ CY. In UBMT, it is unclear which regimen is sufficient to prevent graft failure. Intensive regimens are necessary to obtain full engraftment, but may lead to viral infections such as Epstein-Barr virus-induced B lymphocyte proliferative disorders. Jabado et al 16 reports 44 children with inborn errors treated with BMT using T celldepleted bone marrow and two monoclonal antibodies. Engraftment rate was 69.8% and fatal infections occurred in 43.2% of patients. We used CY ϩ TBI, which induces relatively intensive immunosuppression and is widely used.
Age at time of HSCT is another difficult problem for CGD patients. Primary immunodeficiency patients have a
Bone Marrow Transplantation better prognosis if HSCT is performed at an early age. A report of 149 patients with primary immunodeficiency diseases shows a significantly better survival rate if BMT is performed before 4 years of age. 17 A summary of 13 reports of BMT for patients with CGD found the medium age at BMT to be 7 years (ranging from 0.4 years to 15 years of age), with older patients at increased risk of GVHD and HSCT complications. 12 Furthermore, older CGD patients have underlying infections and organ dysfunctions due to repeated infections or drugs.
On the other hand, the survival of CGD patients has improved recently and the severity of CGD is not uniform. [1] [2] [3] [4] A report of 368 patients with CGD showed a significantly higher mortality in patients with the X-linked recessive form of the disease. 4 It is difficult to predict which patient will experience severe infections repeatedly and have a poor prognosis. Therefore, it is important to identify high-risk patients and select them as HSCT candidates early in childhood before they suffer repeated, uncontrolled infections.
Although underlying infection increases the risk of HSCT, CGD may well take a fatal course without HSCT. The patient we describe here had therapy-resistant pneumonitis and Aspergillus osteomyelitis. After his infections improved following 94 granulocyte transfusions, we considered that a transplant might be the last chance of helping him. HSCT is not always contraindicated in patients with CGD with severe infection. Ozsahin et al 8 reported an 8-year-old patient with CGD treated successfully by HLAgenoidentical BMT and granulocyte transfusions during invasive aspergillosis. The case we report also shows HSCT may be life-saving for some patients with severe infection, in spite their critical condition.
In conclusion, patients with CGD can be cured by UBMT. However, identification of which patients require UBMT treatment, timing of the procedure and optimum conditioning regimen must be defined in order to minimize the risks of toxicity, graft failure, and infection.
